Get started
Author

Daniel Fareed

Erythropoietin-Induced Thrombosis as a Result of Increased Inflammation and Thrombin Activatable Fibrinolytic Inhibitor
2004 · Mahmut Tobu, Omer Iqbal, et al. · Clinical and Applied Thrombosis/Hemostasis · 79
Survival of Heparins, Oral Anticoagulants, and Aspirin after the Year 2010
2008 · Jawed Fareed, Debra Hoppensteadt, et al. · Seminars in Thrombosis and Hemostasis · 73
PDF
Are All Low Molecular Weight Heparins Equivalent in the Management of Venous Thromboembolism?
2007 · Jawed Fareed, Walter Jeske, et al. · Clinical and Applied Thrombosis/Hemostasis · 17
Survival of Heparins, Oral Anticoagulants, and Aspirin after the Year 2010
2008 · Jawed Fareed, Debra Hoppensteadt, et al. · Seminars in Thrombosis and Hemostasis · 14
PDF
Blood Levels of Nitric Oxide, C-Reactive Protein, and Tumor Necrosis Factor-α Are Upregulated in Patients with Malignancy-Associated Hypercoagulable State: Pathophysiologic Implications
2004 · D. Fareed, O. Iqbal, et al. · Clinical and Applied Thrombosis/Hemostasis · 14
Betaine Induced Release of Tissue Factor Pathway Inhibitor and Nitric Oxide: Implications in the Management of Cardiovascular Disease
2006 · Omer Iqbal, D Fareed, et al. · The FASEB Journal · 8
Increased levels of inflammatory mediators in lung cancer and their modulation by oral anticoagulant treatment
2006 · D. A. Hoppensteadt, A. Ciftci, et al. · Journal of Clinical Oncology · 6
ProteinChip Array Profiling and Markers of Inflammation and Thrombin Generation in Plasma Samples from Lung Cancer Patients and Their Modulation by Chemotherapy with or without Warfarin Anticoagulation.
2007 · Muzaffer Demir, A. Ciftci, et al. · Blood · 5
Global Anticoagulant Effects of a Synthetic Anti-Factor Xa Inhibitor (DX-9065a): Implications for Interventional Use
2003 · Mahmut Tobu, Omer Iqbal, et al. · Clinical and Applied Thrombosis/Hemostasis · 4
PDF
Argatroban, Not Lepirudin or Bivalirudin, Treatment Results in the Generation of Nitric Oxide during Parenteral Administration.
2004 · Jeanine M. Walenga, Daniel Fareed, et al. · Blood · 3
Role of PAI-1 and TAFI in the mediation of fibrinolytic deficit in cancer patients
2004 · M. R. Florian-Kujawski, D. Hoppensteadt, et al. · Journal of Clinical Oncology · 3
Current Developments in Anticoagulant and Antithrombotic Agents
1999 · Jawed Fareed, Debra Hoppensteadt, et al. · Springer eBooks · 3
Increased Procalcitonin Levels in End Stage Renal Disease and Chronic Kidney Disease as An Indicator of Inflammatory Activation
2008 · Vinod Bansal, Daniel Fareed, et al. · Blood · 2
Modulation of Platelet Function by Recombinant Thrombomodulin Hematologic Implications.
2007 · Cafer Adiguzel, Omer Iqbal, et al. · Blood · 2
Modulation of Platelet Function by Recombinant Thrombomodulin Hematologic Implications
2008 · Cafer Adiguzel, Omer Iqbal, et al. · The FASEB Journal · 1
Pathogenesis of Atrial Fibrillation‐potential Role of Inflammatory Response.
2006 · Jawed Fareed, D Hoppensteadt, et al. · The FASEB Journal · 1
Enoxaparin (E) and warfarin (W) differentially regulate tissue factor (TF), tissue factor pathway inhibitor (TFPI) and thrombin activatable fibrinolytic inhibitor (TAFI) in cancer patients with thrombosis
2005 · J. Fareed, D. Hoppensteadt, et al. · Journal of Clinical Oncology · 1
Upregulation of procalcitonin in cancer patients with venous thrombosis is independent of sepsis
2008 · J. Fareed, O. Iqbal, et al. · Journal of Clinical Oncology
Defibrotide Interactions with Anticoagulant Drugs. Developmental Implications.
2008 · Debra Hoppensteadt, Josephine Cunanan, et al. · The FASEB Journal
Comparative Study on the Anticoagulant Effects of Unfractionated and Low Molecular Weight Heparins, Lower Low Molecular Weight Heparins and Pentasaccahride as Measured by Whole Blood Act, Anti-xa and a Newly Developed Prothrombinase Induced Clotting Time
2007 · R. Wahi, D. Hoppensteadt, et al. · Journal of Thrombosis and Haemostasis
Recombinant Thrombomodulin Does Not Cross React With Anti-heparin Platelet Factor 4 Antibodies. Potential Implication for Anticoagulation of Heparin-induced Thrombocytopenia Patients
2007 · D. Fareed, D. Hoppensteadt, et al. · Journal of Thrombosis and Haemostasis
Nitric oxide and asymmetric dimethylarginine and CD 40 ligand levels in malignancy associated thrombosis and their modulation by anticoagulants
2007 · D. Hoppensteadt, D. Fareed, et al. · Journal of Clinical Oncology
Up-regulation of inflammatory and thrombotic mediators in lung cancer and their modulation by oral anticoagulantion
2007 · J. Fareed, A. Ciftci, et al. · Journal of Clinical Oncology
Nitric Oxide and Asymmetric Dimethylarginine Levels in Malignancy Associated Thrombosis and Their Modulation by Anticoagulants
2007 · Debra Hoppensteadt, Walter Jeske, et al. · The FASEB Journal
Nitric Oxide and Asymmetric Dimethlyarginine Levels in Malignancy Associated Thrombosis and Their Modulaiton by Anticoagulants.
2006 · Debra Hoppensteadt, Daniel Fareed, et al. · Blood
Works count: 34
Citation count: 236
H-index: 6
I10-index: 5
Year
Topic
Type